BTK A428D is a recurrent, pan-resistance mutation in patients with acquired resistance to BTK degraders By webmaster / June 23, 2026
NRX-4972, a selective, oral, Aurora kinase A degrader, demonstrates increased efficacy in an SCLC tumor model, and greater in vitro synergy than an AURKA inhibitor By webmaster / April 21, 2026
NRX-0305: an Orally Bioavailable, CNS Penetrant, Pan-Mutant BRAF Degrader Demonstrates Robust Efficacy in Intracranial Models of Melanoma Brain Metastasis and Primary Glioma By webmaster / April 21, 2026
NRX-0305 is an Orally Bioavailable, Pan-Mutant BRAF Degrader that Exhibits Single Agent and Combination Efficacy with MEKi or anti-EGFR Across Class 1/2/3 BRAF Mutant Cancers By webmaster / April 21, 2026
Combinatorial Optimization of Degrader-Antibody Conjugates Enabled by Automation By webmaster / April 2, 2026
Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Shows High Clinical Activity and Tolerable Safety in Patients with Waldenström Macroglobulinemia: Updated Results from an Ongoing Phase 1a/b Study By webmaster / December 12, 2025
Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed/refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial By webmaster / December 8, 2025
Molecular and structural basis of pan-resistance to BTK targeting therapies via BTK A428D mutation By webmaster / December 6, 2025
Degrader Antibody Conjugates (DACs): Targeted Protein Degraders (TPDs) as Next Generation Antibody Drug Conjugate (ADC) Payloads By webmaster / October 29, 2025
